

David D Kim

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4015930/publications.pdf>

Version: 2024-02-01

39
papers

1,309
citations

430874

18
h-index

361022

35
g-index

40
all docs

40
docs citations

40
times ranked

2092
citing authors

#	ARTICLE	IF	CITATIONS
1	The Impact of Broader Value Elements on Cost-Effectiveness Analysis: Two Case Studies. <i>Value in Health</i> , 2022, 25, 1336-1343.	0.3	4
2	A Systematic Review of Economic Evaluations of COVID-19 Interventions: Considerations of Non-Health Impacts and Distributional Issues. <i>Value in Health</i> , 2022, 25, 1298-1306.	0.3	10
3	Consideration Of Value-Based Pricing For Treatments And Vaccines Is Important, Even In The COVID-19 Pandemic. <i>Health Affairs</i> , 2021, 40, 53-61.	5.2	29
4	Differences in the Selection of Health State Utility Values by Sponsorship in Published Cost-Effectiveness Analyses. <i>Medical Decision Making</i> , 2021, 41, 366-372.	2.4	3
5	An Evidence Review of Low-Value Care Recommendations: Inconsistency and Lack of Economic Evidence Considered. <i>Journal of General Internal Medicine</i> , 2021, 36, 3448-3455.	2.6	12
6	Cost-effectiveness Analysis of Nutrition Facts Added-Sugar Labeling and Obesity-Associated Cancer Rates in the US. <i>JAMA Network Open</i> , 2021, 4, e217501.	5.9	3
7	Do Centers for Medicare and Medicaid Services Quality Measures Reflect Cost-Effectiveness Evidence?. <i>Value in Health</i> , 2021, 24, 1586-1591.	0.3	5
8	Frequency and impact of the inclusion of broader measures of value in economic evaluations of vaccines. <i>Vaccine</i> , 2021, 39, 6727-6734.	3.8	5
9	Influence of Modeling Choices on Value of Information Analysis: An Empirical Analysis from a Real-World Experiment. <i>Pharmacoeconomics</i> , 2020, 38, 171-179.	3.3	0
10	Cost-Effectiveness of a National Sugar-Sweetened Beverage Tax to Reduce Cancer Burdens and Disparities in the United States. <i>JNCI Cancer Spectrum</i> , 2020, 4, pkaa073.	2.9	6
11	Measuring Economic Effects in Valuing Therapies: An Application to COVID-19 in China. <i>Value in Health</i> , 2020, 23, 1405-1408.	0.3	12
12	Perspective and Costing in Cost-Effectiveness Analysis, 1974-2018. <i>Pharmacoeconomics</i> , 2020, 38, 1135-1145.	3.3	109
13	Analyzing the Cost Effectiveness of Policy Responses for COVID-19: The Importance of Capturing Social Consequences. <i>Medical Decision Making</i> , 2020, 40, 251-253.	2.4	19
14	Growth and capacity for cost-effectiveness analysis in Africa. <i>Health Economics (United Kingdom)</i> , 2020, 29, 945-954.	1.7	34
15	Are low and middle-income countries prioritising high-value healthcare interventions?. <i>BMJ Global Health</i> , 2020, 5, e001850.	4.7	13
16	Using QALYs versus DALYs to measure cost-effectiveness: How much does it matter?. <i>International Journal of Technology Assessment in Health Care</i> , 2020, 36, 96-103.	0.5	26
17	Prevention of non-communicable disease: best buys, wasted buys, and contestable buys. <i>BMJ</i> , The, 2020, 368, m141.	6.0	25
18	Crisis into opportunity: can COVID-19 help set a path to improved health care efficiency?. <i>American Journal of Managed Care</i> , 2020, 26, 369-370.	1.1	15

#	ARTICLE	IF	CITATIONS
19	Leveraging Cumulative Network Meta-analysis and Value of Information Analysis to Understand the Evolving Value of Medical Research. <i>Medical Decision Making</i> , 2019, 39, 119-129.	2.4	5
20	Taking stock of cost-effectiveness analysis of healthcare in China. <i>BMJ Global Health</i> , 2019, 4, e001418.	4.7	19
21	Preventable Cancer Burden Associated With Poor Diet in the United States. <i>JNCI Cancer Spectrum</i> , 2019, 3, pkz034.	2.9	95
22	Adherence to the iDSI reference case among published cost-per-DALY averted studies. <i>PLoS ONE</i> , 2019, 14, e0205633.	2.5	27
23	Comparative Modeling to Inform Health Policy Decisions: A Step Forward. <i>Annals of Internal Medicine</i> , 2019, 171, 851.	3.9	6
24	Cost Effectiveness of Nutrition Policies on Processed Meat: Implications for Cancer Burden in the U.S.. <i>American Journal of Preventive Medicine</i> , 2019, 57, e143-e152.	3.0	18
25	Targeted Incentive Programs For Lung Cancer Screening Can Improve Population Health And Economic Efficiency. <i>Health Affairs</i> , 2019, 38, 60-67.	5.2	8
26	Use and Misuse of Cost-Effectiveness Analysis Thresholds in Low- and Middle-Income Countries: Trends in Cost-per-DALY Studies. <i>Value in Health</i> , 2018, 21, 759-761.	0.3	108
27	Association Between the Publication of Clinical Evidence and the Use of Bariatric Surgery. <i>Obesity Surgery</i> , 2018, 28, 1321-1328.	2.1	8
28	Future Directions for Cost-effectiveness Analyses in Health and Medicine. <i>Medical Decision Making</i> , 2018, 38, 767-777.	2.4	58
29	Economic Value of Greater Access to Bariatric Procedures for Patients With Severe Obesity and Diabetes. <i>Medical Care</i> , 2018, 56, 583-588.	2.4	20
30	Specialty Drug Coverage Varies Across Commercial Health Plans In The US. <i>Health Affairs</i> , 2018, 37, 1041-1047.	5.2	45
31	Integrating value of research into NCI Clinical Trials Cooperative Group research review and prioritization: A pilot study. <i>Cancer Medicine</i> , 2018, 7, 4251-4260.	2.8	8
32	Comparing the cost-per-QALYs gained and cost-per-DALYs averted literatures. <i>Gates Open Research</i> , 2018, 2, 5.	1.1	24
33	Comparing the cost-per-QALYs gained and cost-per-DALYs averted literatures. <i>Gates Open Research</i> , 2018, 2, 5.	1.1	15
34	The influence of time horizon on results of cost-effectiveness analyses. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2017, 17, 615-623.	1.4	51
35	New Metrics for Economic Evaluation in the Presence of Heterogeneity: Focusing on Evaluating Policy Alternatives Rather than Treatment Alternatives. <i>Medical Decision Making</i> , 2017, 37, 930-941.	2.4	8
36	Estimating the Medical Care Costs of Obesity in the United States: Systematic Review, Meta-Analysis, and Empirical Analysis. <i>Value in Health</i> , 2016, 19, 602-613.	0.3	271

#	ARTICLE	IF	CITATIONS
37	Cost-effectiveness model for hepatitis C screening and treatment: Implications for Egypt and other countries with high prevalence. <i>Global Public Health</i> , 2015, 10, 296-317.	2.0	55
38	Cost-Effectiveness of Various Interventions for Newly Diagnosed Diabetic Macular Edema. <i>Ophthalmology</i> , 2013, 120, 1835-1842.	5.2	48
39	Cost-effectiveness of Medications Compared With Laser Trabeculoplasty in Patients With Newly Diagnosed Open-Angle Glaucoma. <i>JAMA Ophthalmology</i> , 2012, 130, 497.	2.4	76